Literature DB >> 16835931

Extensive acrochordons and pancreatic islet-cell tumors in tuberous sclerosis associated with TSC2 mutations.

J Lawrence Merritt1, Dawn Marie R Davis, Mark R Pittelkow, Dusica Babovic-Vuksanovic.   

Abstract

Acrochordons are frequently encountered benign skin lesions that may occasionally represent underlying pathology. Pancreatic islet-cell tumors are rare neoplasms and few cases have been described in patients with tuberous sclerosis complex (TSC). A 39-year-old man presenting in acute renal failure was referred to us for further diagnostic evaluation of coincidentally noted dysmorphic features. Physical examination revealed over 1,000 acrochordons in addition to findings meeting criteria for TSC. The diagnosis was confirmed by disclosure of mutation in the TSC2 gene. Further evaluation revealed pancreatic islet cell tumors. Acrochordons are a common skin lesion, but when presenting in an atypical manner or unusual number may be a sign of TSC and underlying occult pathology thereby warranting evaluation of TSC2. Additionally, mutations in TSC2 gene may be a risk factor for developing pancreatic islet-cell tumors. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16835931     DOI: 10.1002/ajmg.a.31351

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  9 in total

1.  Pancreatic tumors in children and young adults with tuberous sclerosis complex.

Authors:  Gonca Koc; Sam Sugimoto; Rachel Kuperman; Bamidele F Kammen; S Pinar Karakas
Journal:  Pediatr Radiol       Date:  2016-09-17

Review 2.  Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.

Authors:  Robert T Jensen; Marc J Berna; David B Bingham; Jeffrey A Norton
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

Review 3.  Hereditary pancreatic cancer: molecular bases and their application in diagnosis and clinical management: a guideline of the TTD group.

Authors:  P Pérez Segura; C Guillén Ponce; T Ramón Y Cajal; R Serrano Blanch; E Aranda
Journal:  Clin Transl Oncol       Date:  2012-07-19       Impact factor: 3.405

Review 4.  Endocrine tumours in neurofibromatosis type 1, tuberous sclerosis and related syndromes.

Authors:  Maya B Lodish; Constantine A Stratakis
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2010-06       Impact factor: 4.690

Review 5.  Rare and unusual endocrine cancer syndromes with mutated genes.

Authors:  Maya B Lodish; Constantine A Stratakis
Journal:  Semin Oncol       Date:  2010-12       Impact factor: 4.929

Review 6.  Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets.

Authors:  Chandra K Maharjan; Po Hien Ear; Catherine G Tran; James R Howe; Chandrikha Chandrasekharan; Dawn E Quelle
Journal:  Cancers (Basel)       Date:  2021-10-12       Impact factor: 6.639

Review 7.  Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment.

Authors:  Bing-Hua Jiang; Ling-Zhi Liu
Journal:  Drug Resist Updat       Date:  2008-04-28       Impact factor: 18.500

Review 8.  Tuberous Sclerosis Complex with rare associated findings in the gastrointestinal system: a case report and review of the literature.

Authors:  Larissa Brussa Reis; Daniele Konzen; Cristina Brinckmann Oliveira Netto; Pedro Moacir Braghirolli Braghini; Gabriel Prolla; Patricia Ashton-Prolla
Journal:  BMC Gastroenterol       Date:  2020-11-23       Impact factor: 3.067

9.  In silico regulatory analysis for exploring human disease progression.

Authors:  Dustin T Holloway; Mark Kon; Charles DeLisi
Journal:  Biol Direct       Date:  2008-06-18       Impact factor: 4.540

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.